Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-393 in Healthy Subjects
NCT04260438Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-393 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration and Maximum Plasma Concentration. Started Apr 2020; status: completed.
02
Drugs
CKD-393
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04260438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260438.